Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NYSE:CPHI NASDAQ:LIXT NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$0.89+0.6%$1.09$0.87▼$2.55$16.79M0.52225,689 shs292,717 shsCPHIChina Pharma$1.49+0.7%$1.69$1.20▼$3.35$4.86M0.87107,331 shs12,669 shsLIXTLixte Biotechnology$3.41+3.0%$3.07$0.64▼$5.14$15.55M0.43847,654 shs131,021 shsMBRXMoleculin Biotech$0.57-4.9%$0.57$0.25▼$3.65$17.19M1.394.40 million shs1.94 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics-3.59%-1.37%-20.98%-35.16%-27.46%CPHIChina Pharma+3.50%+1.37%-16.85%-33.33%-92.68%LIXTLixte Biotechnology-5.97%-15.13%-22.12%+150.76%+80.87%MBRXMoleculin Biotech+6.46%-7.89%-23.07%-37.26%-76.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics3.3467 of 5 stars3.55.00.00.02.41.70.6CPHIChina Pharma0.9256 of 5 stars0.05.00.00.02.20.80.0LIXTLixte Biotechnology0.1087 of 5 stars0.02.00.00.01.00.80.0MBRXMoleculin Biotech2.9185 of 5 stars3.54.00.00.01.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$8.50855.06% UpsideCPHIChina Pharma 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/AMBRXMoleculin Biotech 3.00Buy$4.00604.72% UpsideCurrent Analyst Ratings BreakdownLatest CPHI, MBRX, CMMB, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.00(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$0.51 per shareN/ACPHIChina Pharma$4.40M1.11N/AN/A$0.70 per share2.13LIXTLixte BiotechnologyN/AN/AN/AN/A$0.14 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A($0.24) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$13.94M-$0.59N/AN/AN/AN/A-94.71%-76.53%N/ACPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ALIXTLixte Biotechnology-$3.59M-$1.29N/A∞N/AN/AN/A-222.90%11/10/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%N/ALatest CPHI, MBRX, CMMB, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CMMBChemomab Therapeutics-$0.20-$0.09+$0.11-$0.09N/AN/A8/12/2025Q2 2025MBRXMoleculin Biotech-$0.39-$0.49-$0.10-$0.49N/AN/A8/7/2025Q2 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A7.425.33CPHIChina Pharma0.220.790.26LIXTLixte BiotechnologyN/A1.841.84MBRXMoleculin BiotechN/A1.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%CPHIChina PharmaN/ALIXTLixte Biotechnology5.10%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%CPHIChina Pharma17.32%LIXTLixte Biotechnology14.80%MBRXMoleculin Biotech2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2018.86 million16.61 millionNot OptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableLIXTLixte Biotechnology44.56 million3.89 millionNot OptionableMBRXMoleculin Biotech2030.29 million29.65 millionNot OptionableCPHI, MBRX, CMMB, and LIXT HeadlinesRecent News About These CompaniesMoleculin Biotech Holds 2025 Annual Stockholders MeetingAugust 19 at 2:05 PM | msn.comMoleculin Biotech Releases New Corporate PresentationAugust 19 at 9:00 AM | msn.comHC Wainwright Analysts Raise Earnings Estimates for MBRXAugust 17, 2025 | americanbankingnews.comMoleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comMoleculin Biotech Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMoleculin Biotech, Inc.: Moleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 14, 2025 | finanznachrichten.deMoleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last yearAugust 14, 2025 | msn.comMoleculin Biotech sees cash runway into Q4August 14, 2025 | msn.comMoleculin Biotech Misses Fiscal Q2 EPSAugust 14, 2025 | aol.comAMoleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 13, 2025 | globenewswire.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer ...August 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation UpdateAugust 1, 2025 | tipranks.comMoleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 31, 2025 | finanznachrichten.deMoleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 30, 2025 | globenewswire.comMoleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comMoleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMoleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic PartnershipsJuly 17, 2025 | globenewswire.comMoleculin Biotech enters $6.5 million at-the-market equity offering ...July 13, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, MBRX, CMMB, and LIXT Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$0.89 +0.01 (+0.56%) Closing price 03:59 PM EasternExtended Trading$0.86 -0.04 (-3.93%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.China Pharma NYSE:CPHI$1.50 +0.02 (+1.01%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Lixte Biotechnology NASDAQ:LIXT$3.41 +0.10 (+3.02%) Closing price 04:00 PM EasternExtended Trading$3.62 +0.21 (+6.28%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Moleculin Biotech NASDAQ:MBRX$0.57 -0.03 (-4.88%) Closing price 04:00 PM EasternExtended Trading$0.57 +0.01 (+1.13%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Broadcom Named in Apple’s $100B U.S. Investment Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access